Difference between revisions of "MSK Biomarker Ctte"
Jump to navigation
Jump to search
Line 6: | Line 6: | ||
The MSK Biomarker Committee seeks to develop a quantitative Profile for MSK. | The MSK Biomarker Committee seeks to develop a quantitative Profile for MSK. | ||
− | == | + | ==Meetings== |
− | *[[Media:2017_10-17_QIBA_MSK_Biomarker_Cmte_Call_Summary-FINAL.pdf|October 17, 2017 | + | '''Approved call summaries:''' |
− | *[[Media:2017_09-19_QIBA_MSK_Biomarker_Cmte_Call_Summary-FINAL.pdf|September 29, 2017 | + | *[[Media:2017_10-17_QIBA_MSK_Biomarker_Cmte_Call_Summary-FINAL.pdf|October 17, 2017]] |
− | *[[Media:2017_07-18_QIBA_MSK_Biomarker_Cmte_Call_Summary-FINAL.pdf|July 18, 2017 | + | *[[Media:2017_09-19_QIBA_MSK_Biomarker_Cmte_Call_Summary-FINAL.pdf|September 29, 2017]] |
+ | *[[Media:2017_07-18_QIBA_MSK_Biomarker_Cmte_Call_Summary-FINAL.pdf|July 18, 2017]] | ||
'''''[[MSK Biomarker Committee Call Summaries Archive]]''''' | '''''[[MSK Biomarker Committee Call Summaries Archive]]''''' |
Revision as of 20:35, 22 November 2017
- Co-chairs: Thomas M. Link, MD, PhD; Xiaojuan Li, PhD
- Secretary: Susan Weinmann
The MSK Biomarker Committee seeks to develop a quantitative Profile for MSK.
Meetings
Approved call summaries:
MSK Biomarker Committee Call Summaries Archive